Compare Analog Devices, Inc. (ADI) vs Novavax Inc (NVAX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Analog Devices, Inc. vs Novavax Inc — how do they compare? Analog Devices, Inc. trades at $387 (market cap $184.62B), while Novavax Inc trades at $9.42 (market cap $1.56B). The key difference: Analog Devices, Inc. is far larger — about 118.3× Novavax Inc's market cap, and Analog Devices, Inc. pays a 1.16% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ADI | NVAX | |
|---|---|---|
Market Cap | $184.62B | $1.56B |
Sector | Technology | Health |
52-Week High | $445.48 | $11.19 |
52-Week Low | $220.68 | $6.22 |
Enterprise Value | $189.87B | $1.06B |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $379.03, up 0.5% with neutral technical signals. The company demonstrates strong fundamentals with consistent earnings beats (Q3-Q1 2026) and robust profitability (26% net margin). Recent acquisition of Empower Semiconductor and AI-driven semiconductor demand provide growth catalysts. Cash flow remains positive at $508M in 2025, though net cash flow is projected to decline to $61M in 2026.
Outlook remains positive with 79.6% analyst buy ratings and $471 consensus price target (24% upside). Key risks include elevated valuation multiples (P/E 57.9) and debt-to-asset ratio increase to 17.9%. The stock offers dividend income ($1.10 H1-26) while benefiting from semiconductor industry tailwinds, though margin sustainability and competitive pressures warrant monitoring.
Novavax (NVAX) trades at $9.46, down 2.87% on the day, with a bullish technical signal from moving averages. The company reported strong revenue of $1.12B in 2025 and has beaten EPS estimates for three consecutive quarters. Analyst consensus is bullish with a $14.00 price target, though negative cash flow and shareholder equity remain concerns. Recent news highlights investor attention and participation in healthcare conferences.
Outlook: Potential upside exists from continued earnings beats and vaccine demand, but risks include persistent cash burn, high debt, and competitive pressures. The stock offers speculative growth opportunity amid volatile biotech sentiment, requiring careful risk assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
